Related Experiment Video
Updated: Apr 21, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.1K
Balancing ischaemia and bleeding risks with novel oral anticoagulants
Usman Baber1, Ioannis Mastoris1, Roxana Mehran1
1Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, PO Box 1030, New York, NY 10029, USA.
Nature Reviews. Cardiology
|November 5, 2014
Summary
Novel oral anticoagulants (NOACs) offer a safer alternative to Vitamin K antagonists (VKAs) for treating venous thromboembolism and preventing strokes in atrial fibrillation patients. NOACs demonstrate improved safety and efficacy across various clinical scenarios.
Area of Science:
- Pharmacology
- Cardiology
- Hematology
Background:
- Vitamin K antagonists (VKAs) were the standard for venous thromboembolism (VTE) and atrial fibrillation (AF) thromboprophylaxis.
- VKAs require frequent monitoring and have drug-drug interaction issues.
- Novel oral anticoagulants (NOACs) emerged in 2009 as alternatives with predictable profiles.
Purpose of the Study:
- To compare the clinical effects of NOACs versus VKAs.
- To evaluate NOACs in different clinical scenarios, including acute coronary syndrome, VTE treatment, and AF thromboprophylaxis.
- To assess the evolving role of NOACs in diverse patient populations.
Main Methods:
- Comparative analysis of clinical outcomes.
- Review of pharmacological profiles and safety data.
- Evaluation of efficacy and bleeding risks in various patient groups.
Main Results:
- NOACs show incremental bleeding risks with modest benefits as adjunctive therapy in acute coronary syndrome.
- NOACs have a safer profile and similar efficacy to VKAs for VTE treatment.
- NOACs provide the greatest benefits in AF thromboprophylaxis, reducing ischemic and hemorrhagic events, and potentially mortality.
Conclusions:
- NOACs offer a favorable risk-benefit balance compared to VKAs in AF thromboprophylaxis.
- NOACs are effective and safer for VTE treatment.
- The application of NOACs is expanding, with ongoing research in specific patient populations like those with renal impairment.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:29Venous Thrombosis III: Interprofessional Care
480
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
480
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:30Venous Thrombosis IV: Nursing Management
405
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
405
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K